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The discovery of arteannuin (qinghaosu) in the 20th Century was a major advance for medicine. Besides 
functioning as a malaria therapy, arteannuin is a pharmacological agent in a range of other diseases, but 
its mechanism of action remains obscure. In this study, the reverse docking server PharmMapper was 
used to identify potential targets of arteannuin. The results were checked using the chemical-protein 
interactome servers DRAR-CPI and DDI-CPI, and verified by AutoDock Vina. The results showed that 
neprilysin (also known as CD10), a common acute lymphoblastic leukaemia antigen, was the top disease-
related target of arteannuin. The chemical-protein interactome and docking results agreed with those of 
PharmMapper, further implicating neprilysin as a potential target. Although experimental verification 
is required, this study provides guidance for future pharmacological investigations into novel clinical 
applications for arteannuin.
Uniterms: Arteannuin/chemical-protein interactome. Computational drug repositioning. Neprilysin/
identification. Reverse docking.
INTRODUCTION
Arteannuin (Figure 1) was originally discovered as 
a malaria therapy by Chinese scientists in the 1970s, and 
this discovery constitutes one of the greatest discoveries 
in medicine in the 20th Century (O’Neill, Barton Ward, 
2010; Tu, 2011). Arteannuin is also known as artemisinin, 
artemisine, Qinghaosu, and Huanghuasu (O’Neill et al., 
2010; Tu, 2011). Artemisinin and its derivatives are unique 
among antimalarial drugs because they kill the young 
intraerythrocytic malaria parasite, thereby preventing 
its advancement into a more pathological mature stage 
(White, 2008). More recently, anticancer properties in 
cell lines and animal models have been reported, as has 
anti-schistosomal activity (O’Neill et al., 2010). Five key 
signalling pathways (PI3K-Akt, T-cell receptor, Toll-like 
receptor, TGF-b, and insulin) are reportedly involved in 
arteannunin-mediated anticancer effects (Huang et al., 
2013), but the underlying mechanism of action remains 
ambiguous (O’Neill et al., 2010). 
Drug discovery is a cost- and time-consuming 
venture (Hurle et al., 2013; Volkamer, Rarey, 2014). 
To reduce these expenses, computational approaches 
have been applied to the early drug-development 
pipeline (Volkamer, Rarey, 2014). In silico drug target 
identification, which involves numerous distinct 
algorithms for identifying disease-associated genes and 
FIGURE 1 - The structure of arteannuin downloaded from 
PubChem (CID: 68827).
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proteins, is the first step in the drug discovery pipeline 
(Liu et al., 2010). Reverse docking, first proposed in 2001, 
refers to the computational docking of a specific small 
molecule of interest (natural product, lead, or synthetic 
compound) to a protein structure database (Chen, Zhi, 
2001). This approach can be used to discover new targets 
for existing drugs and natural compounds, investigate 
the polypharmcology and molecular mechanism of a 
substance, find alternative drug information through 
drug repositioning, and predict adverse drug reactions 
and drug toxicity (Aeri, Kyoungyeul, Dongsup, 2016). 
This computational method is also particularly useful for 
identifying targets for a given ligand (Aeri, Kyoungyeul, 
Dongsup, 2016). In our previous work, we use reverse 
docking to reveal that carbonic anhydrase 2 may be a 
potential target of capsaicin, and other research groups 
have also identified capsaicin as a potent inhibitor of 
carbonic anhydrase isoenzymes (Ye, Ling, Chen, 2015). 
Adoption of computational methodologies for drug 
repositioning is rapidly becoming mainstream (Hurle et 
al., 2013). 
In this study, we used computational drug 
repositioning to identify potential targets of arteannuin. 
The reverse docking server PharmMapper was used to 
identify potential targets, and the results were checked 
by AutoDock Vina in PyRx0.8, and the chemical-protein 
interactome servers DRAR-CPI and DDI-CPI. The 
ultimate aim of the study was to gain insight into the 
mechanism of arteannuin in traditional Chinese medicine.
MATERIALS AND METHODS
Target prediction by PharmMapper
PharmMapper (http://59.78.96.61/pharmmapper) 
is a web server for identification of potential drug targets 
that utilises a large-scale reverse pharmacophore mapping 
strategy (Liu et al., 2010). The server hosts a large, in-
house repertoire of pharmacophore database information 
annotated from TargetBank, BindingDB, DrugBank, and 
other potential drug target databases, and includes over 
7000 receptor-based pharmacophore models (Liu et al., 
2010). Recently, it was used to identify anticancer targets 
from eco-friendly waste generated from the peelings of 
Punica granatum (Usha et al., 2014), and also to predict 
and evaluate anticancer targets from cryptotanshinone 
(Yuan et al., 2014). In our previous work, we used 
the server to predict potential targets for Danshensu 
and Tanshinone IIA (Chen, 2014; Chen, Ren, 2014). 
PharmMapper is therefore a powerful tool for target 
prediction.
As described previously (Chen, 2014; Chen, Ren, 
2014), a 2D SDF file for arteannuin was downloaded from 
the PubChem database (CID: 68827) and converted into 
the mol2 format using Discovery Studio Visualizer 3.5. 
The mol2 file was then submitted to the PharmMapper 
server, with the maximum generated conformation set at 
300, all targets set at 7302, and the number of reserved 
matched targets set at 300. Default values were used for 
all other parameters.
Prediction of the chemical-protein interactome 
using DRAR-CPI and DDI-CPI
DRAR-CPI, freely available at http://cpi.bio-x.
cn/drar/, is a server for identifying drug repositioning 
potential and adverse drug reactions via the chemical-
protein interactome (Luo et al., 2011). The natural 
compound plumbagin was recently predicted to interact 
with 78 proteins involved in cell proliferation and 
apoptosis, immunity, and signal transduction following 
bioinformatics analysis that included DRAR-CPI (Qiu 
et al., 2015). We have also used the server previously 
to assess protein targets predicted by the PharmMapper 
server (Chen, 2014). All available evidence suggests that 
DRAR-CPI is a powerful computational tool for drug 
repositioning. 
DDI-CPI (freely accessible at http://cpi.bio-x.cn/
ddi/) is another server that predicts drug-drug interactions 
through implementing a chemical-protein interactome 
(Luo et al., 2014). It can predict the potential usefulness 
of a given compound among 2515 drug molecules in the 
library (85% of which are FDA-approved) (Luo et al., 
2014). DDI-CPI can therefore be used to check the results 
of reverse docking. 
As described previously (Chen, 2014; Qiu et al., 
2015), the 2D structure of arteannuin was downloaded 
from PubChem, and hydrogens and Gasteiger charges 
were added and the file format converted to Mol2 using 
VegaZZ. The resultant file was uploaded to the DRAR-
CPI and DDI-CPI servers, with default values for all 
parameters.
Molecular docking using AutoDock Vina in  
PyRx 0.8
AutoDock Vina in PyRx0.8 is a virtual screening 
software for computational drug discovery that can be 
used to screen libraries of compounds against potential 
drug targets (Trott, Olson, 2010). Recently, this software 
was used for the virtual screening of potential inhibitors 
of high-risk human papillomavirus 16 E6 protein (Kumar 
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et al., 2015), and was also applied in research on eco-
friendly waste from Punica granatum (Usha et al., 
2014).
A redocking study using AutoDock Vina 1.0.2 
was previously reported (Trott, Olson, 2010) that used 
a protein-ligand structure of a target protein (neprilysin-
inhibitor complex, PDB code 1R1H) derived from the 
RCSB Protein Data Bank. The coordinates for the target 
protein and inhibitor bound to chain A were extracted and 
saved in separate files, and receptor and ligand input files 
were prepared using AutoDock Tools 1.5.6 (The Scripps 
Research Institute, CA, USA) (Morris et al., 2009) via the 
graphical user interface. The search space was restricted 
to a box of 24.965 × 22.469 × 22.780 Å (centre = 31.883, 
44.050, 34.157), which was centred on the ligand-binding 
site in the co-crystalised structure. Default values were 
used for all parameters. After docking, the highest scoring 
pose was selected for detailed analysis, and AutoDock 
Vina was used to dock the arteannuin-target protein 
complex.
RESULTS
Targets predicted by PharmMapper
The output of PharmMapper ranks potential target 
pharmacophore models in descending order based on fit 
score (Liu et al., 2010). The top ten disease-related targets 
identified in this study (Table I) revealed neprilysin as 
the highest hit. The neprilysin pharmacophore has three 
hydrophobic groups, one positive group, one negative 
group, two hydrogen donors, and three hydrogen acceptors 
(Figure 2). Pharmacophore visualisations are shown in 
Figure 2.
Prediction of the chemical-protein interactome by 
DRAR-CPI and DDI-CPI
The affinity score, Z-score, and Z’-score of 
arteannuin-neprilysin obtained form the chemical-
protein interactome are shown in Table II, and the binding 
pattern obtained from the DRAR-CPI server is shown 
in Figure 3. The docking score of arteannuin-neprilysin 
obtained using the DDI-CPI server was -7.5 kcal/mol 
(Table II). 
Molecular docking
As illustrated in Figure 4, the top scoring redocking 
pose is very close to the ligand conformation observed in 
the co-crystal structure, with a root mean square deviation 
(RMSD) of only 1.12 Å for non-hydrogen atoms. The 
redocking results indicated that the docking procedure can 
generate a physiologically relevant pose that is suitable 
for further studies. 
TABLE I - Top ten potential disease-related targets of arteannuin predicted by PharmMapper
PDB ID Name Fit Score Disease
1R1H Neprilysin 3.635 Acute lymphocytic leukaemia
1RLB Transthyretin 3.548 Amyloidosis type 1
1RBP Retinol-binding protein 4 3.511 Retinol-binding protein deficiency
1R55 ADAM33 3.418 Asthma
1DIC Complement factor D 3.381 Complement factor D deficiency
1GS4 Androgen receptor 3.303 Androgenetic alopecia
1S9J Dual specificity mitogen-activated protein kinase 1 3.294 Cardiofaciocutaneous syndrome
1G48 Carbonic anhydrase 2 3.259 Autosomal recessive osteopetrosis type 3
1TFG Transforming growth factor beta-2 3.242 Peters anomaly
1PMN Mitogen-activated protein kinase 10 3.114 Epileptic encephalopathy
FIGURE 2 - Alignment of arteannuin and the pharmacophore 
model of neprilysin. (a) Arteannuin features. (b) Pharmacophore 
model. (c) Superimposition of the models in (a) and (b). Note: 
Pharmacophore features are coloured cyan for hydrophobic, 
blue for positively charged, red for negatively charged, green for 
hydrogen bond donor, and magenta for hydrogen bond acceptor 
(Liu et al., 2010).
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Using AutoDock Vina in PyRx 0.8, the binding 
energy of the lowest state of the arteannuin-neprilysin 
complex was calculated as -5.7 kcal/mol (Table III). As 
shown in Figure 5, arteannuin formed one hydrogen bond 
with residue His711. In addition, residues Phe106 and 
Trp693 formed hydrophobic contacts with arteannuin. 
Comparison of the putative binding model of arteannuin 
with the experimentally determined binding model from 
the co-crystal structure (PDB code 1R1H) is shown in 
Figure 5.
DISCUSSION
The potential for computational drug repositioning 
is great since this systematic process can incorporate 
prioritisation information that can accelerate the drug 
discovery process (Hurle et al., 2013). Reverse or 
inverse docking has proven to be a powerful tool for drug 
repositioning and drug rescue (Kharkar, Warrier, Gaud, 
2014). In this study, neprilysin was found to be the top 
disease-related target of arteannuin using the reverse 
docking server PharmMapper (Table I). A pharmacophore 
is a molecular framework that includes the essential 
features responsible for the biological activity of a drug 
(Yang, 2010). The pharmacophore model generated in this 
study is in good agreement with the molecular features 
of arteannuin (Figure 2), which further supports the 
PharmMapper results. 
A chemical-protein interactome is an estimate of 
the strength of interactions between a matrix of drugs 
and multiple human proteins, and adopting a chemical-
protein interactome approach can identify unexpected 
drug-protein interactions from computational strategies 
such as docking, chemical structure comparison, and 
text-mining (Yang et al., 2011). In the DRAR-CPI results 
of the present study, targets with a Z’-score less than -0.5 
were treated as favourable and those with a Z’-score >0.5 
as unfavourable (Luo et al., 2011; Chen, 2014). Based on 
the Z’-score from DRAR-CPI and the docking score from 
DDI-CPI (Table II), neprilysin is a potential candidate 
target of arteannuin that warrants further investigation. 
TABLE II - Results of the arteannuin-neprilysin interactome using DRAR-CPI and DDI-CPI
DRAR-CPI DDI-CPI
PDB ID Affinity Score Z-score Z’-score PDB ID Docking Score 
1R1H -22.9126 0.58101 2.3121 1DMT -7.5 (kcal/mol)
FIGURE 3 - Binding pattern of arteannuin and neprilysin 
(1DMT) obtained using the DRAR-CPI sever. (a) Overview. 
(b) Detailed view. The protein chain is shown in rocket 
representation, ligands are shown in stock representation, and 
key residues are coloured and shown in line representation.
FIGURE 4 - Superimposition of the redocking pose (magenta) 
and the ligand pose in the co-crystal structure (green). The 
receptor is shown in cartoon representation and is coloured 
light orange.
TABLE III - Binding site coordinates for the pose with the lowest binding energy
PDB ID Name Centre (x × y × z) Binding Energy (kcal/mol)
1R1H Neprilysin 31.27 × 44.58 × 34.62 -5.7
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Importantly, the DRAR-CPI and DDI-CPI results were in 
good agreement with the PharmMapper results (Table I).
Protein-ligand interactions can provide an in-
depth understanding of complex processes at a structural 
level (Chen, 2014). As shown in the published protein-
ligand structure used in this study, the original ligand 
BIR interacts with neprilysin (1R1H) via numerous 
complicated interactions that include hydrogen bonds 
with Ala543, Glu584, His711, Arg717, and Asn542; 
hydrophobic interactions with Phe689, Val692, Val580, 
Met579, and Trp693; and p-cation interactions with 
Phe689 (Oefner et al., 2004). Like the original ligand 
BIR, arteannuin may also bind many of these key residues 
(Figure 3 and 5). Residues His583, His587, and Glu646 are 
involved in zinc coordination, and may also participate in 
monodentate or bidentate recognition, depending on the 
ligand (Oefner et al., 2004). Arg717 participates in a salt 
bridge with Asp650 (Oefner et al., 2004), and Phe106, 
Ile558, Phe563, Met579, Val580, Val692, and Trp693 
form a deep lipophilic cavity (Oefner et al., 2004). The 
pharmacological functions of arteannuin may therefore 
be dependent on these interactions.
To gain further insight into the binding mechanism 
between arteannuin and neprilysin, the putative arteannuin 
binding pose was superimposed onto the ligand in the co-
crystal structure (PDB code 1R1H). As seen in Figure 5, 
compared with the ligand in 1R1H, arteannuin occupies 
less space within the binding pocket of neprilysin due to its 
smaller size. Interestingly, we noted that the polar groups 
of both ligands are located at the bottom of the binding 
site, which indicated that hydrophilic protein residues may 
be more important for binding. Indeed, there is a complex 
hydrogen bonding network between the native ligand and 
the neprilysin protein, whereas arteannuin only forms 
one hydrogen bond, with the side chain of His-711, in the 
highest scoring docking pose. Conversely, the residues at 
the top of the binding pocket are more hydrophobic and 
form multiple hydrophobic interactions with both ligands.
As shown in Table I, neprilysin (also known 
as CD10) is an important cell surface marker in the 
diagnosis of human acute lymphocytic leukaemia. It is a 
ubiquitous transmembrane and circulating protease that 
cleaves a broad range of substrates (Oefner et al., 2004; 
Vodovar et al., 2015). First identified in leukaemia as a 
tumour-specific antigen (common acute lymphoblastic 
leukaemia antigen), CD10 is now widely used in cancer 
diagnosis (Maguer-Satta, Besancon, Bachelard-Cascales, 
2011). Arteannuin and its analogues are reported to act as 
effective anticancer chemotherapeutic agents in Molt-4 
human leukaemia cells (Singh, Lai, 2004; Ohgami et al., 
2010; Singh et al., 2011). The results of the present study 
suggest that the anticancer activity of artemisinin in acute 
lymphocytic leukaemia may be related to the targeting of 
neprilysin.
Neprilysin is also known as a neutral endopeptide 
that has been implicated in the catabolism of amyloid beta 
peptides in the brain, which has attracted considerable 
attention, particularly as a potential therapeutic target for 
FIGURE 5 - Comparison of the putative binding mode of arteannuin (yellow) and the experimental BIR ligand-binding mode 
observed in the co-crystal structure (green; PDB code 1R1H). The receptor is shown in light orange cartoon representation. Black 
dashed lines indicate hydrogen bonds. The green solid line represents hydrophobic interactions and green dashed lines show π-π 
interactions. Hydrophobic and hydrophilic residues are represented by orange red surface and dodger blue surface, respectively 
(in right bottom panel).
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Alzheimer’s disease (Hersh, Rodgers, 2008). Arteannuin 
extenuates amyloidogenesis and neuroinflammation in 
APPswe/PS1De9 transgenic mice via inhibition of nuclear 
factor-κB and NLRP3 inflammasome activation (Shi et al., 
2013). Arteannuin may therefore be a potential treatment 
for Alzheimer’s disease via the targeting of neprilysin.
CONCLUSION
In summary, reverse docking revealed neprilysin as a 
potential target of arteannuin, and the results were assessed 
by a chemical-protein interactome approach using DRAR-
CPI, DDI-CPI, and AutoDock Vina. Despite the need 
for further experimental verification, this study provides 
guidance for future pharmacological investigations into 
novel clinical applications for arteannuin, and may have 
implications for the treatment of acute lymphocytic 
leukaemia or Alzheimer’s disease.
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